Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases
Date
2019
Authors
Leo, C.H.
Jelinic, M.
Ng, H.H.
Parry, L.J.
Tare, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Current Opinion in Pharmacology, 2019; 45:42-48
Statement of Responsibility
Chen Huei Leo, Maria Jelinic, Hooi Hooi Ng, Laura J Parry, and Marianne Tare
Conference Name
Abstract
Cardiovascular disease is the most common cause of mortality worldwide, accounting for almost 50% of all deaths globally. Vascular endothelial dysfunction and fibrosis are critical in the pathophysiology of cardiovascular disease. Relaxin, an insulinlike peptide, is known to have beneficial actions in the cardiovascular system through its vasoprotective and antifibrotic effects. However, relaxin has several limitations of peptide-based drugs such as poor oral bioavailability, laborious, and expensive to synthesize. This review will focus on recent developments in relaxin mimetics, their pharmacology, associated signalling mechanisms, and their therapeutic potential for the management and treatment of cardiovascular disease.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2019 Elsevier Ltd. All rights reserved.